CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival:
- PDF / 336,287 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 34 Downloads / 156 Views
ORIGINAL ARTICLE – PERITONEAL SURFACE MALIGNANCY
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative David Roife, MD1,2, Benjamin D. Powers, MD, MS1,2, Mohammad Y. Zaidi, MD, MS3, Charles A. Staley, MD3, Jordan M. Cloyd, MD4, Ahmed Ahmed, MD4, Travis Grotz, MD5, Jennifer Leiting, MD5, Keith Fournier, MD6, Andrew J. Lee, MD6, Jula Veerapong, MD7, Joel M. Baumgartner, MD, MAS7, Callisia Clarke, MD8, Sameer H. Patel, MD9, Ryan J. Hendrix, MD10, Laura Lambert, MD11, Daniel E. Abbott, MD12, Courtney Pokrzywa, MD12, Byrne Lee, MD13, Andrew Blakely, MD13, Jonathan Greer, MD14, Fabian M. Johnston, MD, MHS14, Danielle Laskowitz, PA-C1, Sophie Dessureault, MD, PhD1,2, and Sean P. Dineen, MD, FACS1,2 1
Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa; 2Department of Oncologic Sciences, University of South Florida, Morsani College of Medicine, Tampa; 3Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta; 4Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus; 5Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester; 6Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston; 7Division of Surgical Oncology, Department of Surgery, University of California, San Diego; 8Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee; 9Department of Surgery, University of Cincinnati College of Medicine, Cincinnati; 10Division of Surgical Oncology, Department of Surgery, University of Massachusetts Medical School, Worcester; 11Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City; 12Division of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison; 13Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte; 14Department of Surgery, Johns Hopkins University, Baltimore, MD
ABSTRACT Introduction. CRS/HIPEC is thought to confer a survival advantage for patients with malignant peritoneal mesothelioma (MPM). However, the impact of
Presented at the SSO Advanced Cancer Therapies Meeting in Orlando, Florida, February 15–17, 2020.
Electronic supplementary material The online version of this article (https://doi.org/10.1245/s10434-020-09232-9) contains supplementary material, which is available to authorized users. Ó Society of Surgical Oncology 2020 First Received: 10 June 2020 Accepted: 23 September 2020 S. P. Dineen, MD, FACS e-mail: [email protected]
nonperitoneal organ resection is not clearly defined. We evaluated the impact of major organ resection (MOR) on postoperative outcomes and overall survival (OS). Patients and Methods. The US HIPEC collaborative database (2000–2017) was reviewed for MPM patients who underwent CRS/HIPEC. MOR was defined as total or partial resection of diaphragm, stomach, spleen, pancreas, small bowel,
Data Loading...
